Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Aleva Neurotherapeutics, a Switzerland-based developer of deep neurological implants founded on EPFL research, has received $8m from undisclosed investors in the inaugural close of its ongoing series E round. The spinout has secured European market approval for an electrode-powered deep brain stimulation device for indications such as Parkinson’s and essential tremour, and will now pursue post-market clinical studies as well as market entry in the US. The round increased Aleva’s overall total to at least $63m. Forrestal Capital led a…
